Pharma / Biotech

LC-MS/MS determination of buparlisib, a phosphoinositide 3 kinase inhibitor in rat plasma: application to a pharmacokinetic study.



Related Articles

LC-MS/MS determination of buparlisib, a phosphoinositide 3 kinase inhibitor in rat plasma: application to a pharmacokinetic study.

Biomed Chromatogr. 2020 Feb 28;:e4816

Authors: Wang J, Ming M, Yu L, Chen G, Hao N, Meng Y, Fang L

Abstract
Buparlisib is a selective phosphoinositide 3 kinase inhibitor currently evaluated in clinical trials. We developed and validated an LC-MS/MS coupled with a one-step protein precipitation extraction method for the quantitation of buparlisib in rat plasma. After protein precipitation with acetonitrile, the plasma sample was analyzed by a CORTECS UPLC C18 column, with acetonitrile/0.1% formic acid as the mobile phase system. Mass spectrometric detection was conducted in positive ionization mode, with target quantitative ion pair of m/z 411.2→367.2 for buparlisib. The calibration curve showed good linearity (1.0-3000 ng/mL), with acceptable accuracy (RE ranging from -6.2% to 5.9%) and precision (RSD within 8.2%) values at QC concentrations. Extraction recovery from plasma was 80.9-88.7% and the matrix effect was negligible (92.6-95.2%). The validated method presented a simple quantification method of buparlisib in detail and utilized for a pharmacokinetic study at three dose concentrations after oral administration in Wistar rats.

PMID: 32110828 [PubMed – as supplied by publisher]

Source link






Related posts

HYDROCODONE BITARTRATE AND ACETAMINOPHEN Tablet [Aurolife Pharma, LLC]

Newsemia

ZARXIO (Filgrastim-Sndz) Injection, Solution [Sandoz Inc.]

Newsemia

ALPHAGAN P (Brimonidine Tartrate) Solution/ Drops [Allergan, Inc.]

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy